Polarean Imaging’s chest coil cleared for integration with Philips MRI platforms
Polarean Imaging’s (POLX ) FDA cleared XENOVIEW 3T Chest Coil has passed Philips’ compatibility testing and is now confirmed for use on Philips' latest 3T MRI systems from early 2026.
The company said Philips has validated integration of the coil with 3.0T platforms such as the MR 7700 and Ingenia Elition X, along with associated software upgrade pathways. The confirmation follows FDA clearance for the coil in 2024 and builds on Philips' introduction of Xenon MRI compatibility in 2022 with the MR 7700.
The XENOVIEW 3T Chest Coil is designed to enable healthcare providers using Philips MRI systems to adopt advanced functional lung ventilation imaging as part of routine clinical workflows and research. This is expected to support broader use of non-invasive, quantitative assessments of lung function across a major global installed base.
This milestone marks a major advance in scaling Polarean's Xenon MRI technology internationally and positions the company for faster clinical adoption and revenue generation. Polarean believes the Philips confirmation will help accelerate adoption, expand market penetration and enhance the commercial and clinical value of its platform worldwide.
Polarean's Chief Executive Officer Christopher von Jako, Ph.D. said: "This milestone marks another important advancement in our vision to optimise lung health and prevent avoidable loss by illuminating hidden disease. Compatibility with Philips' state-of-the-art MRI platforms greatly broadens the accessibility of Xenon MRI and will help more hospitals and imaging centres adopt this powerful technology. Equally significant, our FDA-cleared coil's seamless integration with Philips systems positions us to drive adoption by reducing workflow complexity for clinicians, accelerating market penetration and unlocking growth opportunities."
View from Vox
The Philips compatibility confirmation moves Polarean's XENOVIEW coil from regulatory clearance towards real world deployment across a large 3T MRI installed base. It should broaden the addressable market for Xenon lung MRI and give greater visibility on future commercial traction as Philips sites begin adopting the coil from 2026.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
